Irbesartan has a masking effect on dipyridamole stress induced myocardial perfusion defects
Küçük Resim Yok
Tarih
2004
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams & Wilkins
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background and aim The angiotensin 11 type 1 (AT(1)) receptor antagonist irbesartan is used for the treatment of hypertension, but its anti-ischaemic effect is not yet known. Our aim was to assess the effect of irbesartan administration on the diagnostic yield of Tc-99m sestamibi single photon emission computed tomography (SPECT) in patients with coronary artery disease (CAD) after dipyridamole stress. Methods Our study group consisted of 13 patients (11 men and two women; mean age, 53.3 +/- 10.6 years; body mass index, 26.9 +/- 3.3 kg.m(-2)) with angiographically documented CAD. All patients underwent Tc-9m sestamibi SPECT studies at rest, before (STRESS-1) and 2 weeks after irbesartan (150 mg daily) administration (STRESS-2) at dipyridamole stress. The extent and severity of defects were analysed by using visual and quantitative Tc-99m sestamibi SPECT. Results The mean summed stress score was significantly higher during the STRESS-1 study than the STRESS-2 study (13.2 +/- 7.4 vs. 11 +/- 74, P=0.003). The mean size of perfusion defects at stress was significantly larger for the STRESS-1 group than the STRESS-2 group (17.8% +/- 2.85% vs. 15.3% +/- 2.95%, P=0.01). Conclusion Our study showed that the AT(1) receptor blocker irbesartan reduces the extent and severity of Tc-99m sestamibi perfusion defects after dipyridamole stress in patients with CAD. Irbesartan may alter coronary blood flow reserve. The continued use of irbesartan before stress myocardial perfusion SPECT has a masking effect on stress induced myocardial perfusion defects. For this reason AT(1) receptor blockers must be stopped before stress myocardial perfusion scintigraphic examinations. (C) 2004 Lippincott Williams Wilkins.
Açıklama
Anahtar Kelimeler
Irbesartan, Myocardial Perfusion, Ischaemia, Tc-99m Sestamibi, Coronary-Artery-Disease, Receptor Blockade, Heart, Severity, Exercise, Extent, State
Kaynak
Nuclear Medicine Communications
WoS Q Değeri
Q2
Scopus Q Değeri
Q3
Cilt
25
Sayı
2
